PRME PEER ANALYSIS

Prime Medicine, Inc. Common Stock — metric-by-metric comparison with peers and the industry median

PRMEPrime Medicine, Inc. Common Stock

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

PRMEIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	PRME	MSB	TLX	RTALB	CSL	Ind. Median
P/E	—	—	—	4.89●	29.44	17.91
P/B	8.94	—	6.37	0.61●	2.20	3.51
EV/EBITDA	—	—	120.14	74.61	10.21●	14.82
P/S	169.90	31.61	3.24	6.67	2.62●	10.89

Financial Health
Metric	PRME	MSB	TLX	RTALB	CSL	Ind. Median
Current Ratio	3.80●	—	1.43	1.21	2.57	5.90
Debt/Equity	149.3%	—	112.3%	1.2%●	67.4%	10.9%
NetDebt/EBITDA	0.11●	—	13.13	0.90	2.22	1.15

Profitability
Metric	PRME	MSB	TLX	RTALB	CSL	Ind. Median
Net Margin	-4,917.6%	-115.3%	-0.9%	136.3%●	9.2%	-125.7%
ROE	-216.1%	-11.3%	-1.8%	15.1%●	7.7%	-47.5%
ROA	-63.7%	-8.6%	-0.7%	13.1%●	3.8%	-35.8%
EBITDA Margin	-4,732.2%	-76.6%	3.0%	9.0%	32.8%●	-105.8%

Growth + Dividend
Metric	PRME	MSB	TLX	RTALB	CSL	Ind. Median
Rev. Growth	-90.3%	410.4%●	56.3%	24.0%	4.8%	5.1%
NI Growth	—	—	—	134.0%●	-39.4%	12.1%
Div. Yield	—	0.0%	—	0.0%	2.5%●	0.2%
Payout	—	0.0%	—	0.0%	103.1%	0.0%

Valuation
Metric	PRME	RGNX	ACRS	XOMA	DNA	RIGL	Ind. Median
P/E	—	—	—	23.77	—	2.09●	17.91
P/B	8.94	33.03	4.99	6.63	1.40●	1.91	3.51
EV/EBITDA	—	—	—	15.53	—	5.04●	14.82
P/S	169.90	7.93	85.60	20.67	4.38	2.54●	10.89

Financial Health
Metric	PRME	RGNX	ACRS	XOMA	DNA	RIGL	Ind. Median
Current Ratio	3.80	2.62	4.03	3.59	5.15●	2.62	5.90
Debt/Equity	149.3%	337.1%	1.4%●	110.5%	92.7%	11.4%	10.9%
NetDebt/EBITDA	0.11	0.35	1.46	0.59	-0.18	-0.77●	1.15

Profitability
Metric	PRME	RGNX	ACRS	XOMA	DNA	RIGL	Ind. Median
Net Margin	-4,917.6%	-330.2%	-832.6%	87.0%	-215.4%	121.5%●	-125.7%
ROE	-216.1%	-196.4%	-48.4%	31.9%	-55.8%	174.1%●	-47.5%
ROA	-63.7%	-69.6%	-35.1%	13.0%	-26.2%	107.0%●	-35.8%
EBITDA Margin	-4,732.2%	-261.2%	-843.9%	138.4%●	-149.2%	43.8%	-105.8%

Growth + Dividend
Metric	PRME	RGNX	ACRS	XOMA	DNA	RIGL	Ind. Median
Rev. Growth	-90.3%	-44.0%	-52.9%	-3.3%	-40.5%	47.6%●	5.1%
NI Growth	—	—	—	—	—	879.7%	12.1%
Div. Yield	—	—	—	0.7%	—	—	0.2%
Payout	—	—	—	17.5%	—	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on PRME

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.